Published in Am J Physiol Endocrinol Metab on September 07, 2004
Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes (KML001) | NCT04133922
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 2.73
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol (2012) 2.59
Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42
GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig (2010) 2.40
Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes (2010) 2.34
GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med (2013) 2.31
Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension (2010) 1.94
Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med (2012) 1.70
A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care (2013) 1.51
Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans. Diabetes (2015) 1.50
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med (2008) 1.47
Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle. Diabetes (2015) 1.45
Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes (2012) 1.43
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol (2009) 1.41
The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol (2012) 1.32
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol (2011) 1.31
Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes (2013) 1.28
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology (2008) 1.26
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc (2013) 1.24
Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care (2010) 1.23
Cardiovascular effects of gliptins. Nat Rev Cardiol (2013) 1.23
The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes Care (2011) 1.23
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia (2011) 1.19
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud (2008) 1.19
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol (2010) 1.17
Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care (2011) 1.15
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol (2011) 1.14
The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther (2010) 1.12
Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol (2012) 1.12
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol (2014) 1.12
Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail (2010) 1.11
Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol (2012) 1.10
Defining and achieving treatment success in patients with type 2 diabetes mellitus. Mayo Clin Proc (2010) 1.07
Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol (2011) 1.04
Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Med Sci Monit (2011) 1.03
Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care (2013) 1.03
The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci (2012) 1.01
Understanding the cardiovascular effects of incretin. Diabetes Metab J (2011) 1.01
Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol (2008) 1.00
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol (2014) 1.00
Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin (2011) 1.00
Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol (2012) 0.99
Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care (2012) 0.99
Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol (2013) 0.99
Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes (2009) 0.98
Impact of diabetes on postinfarction heart failure and left ventricular remodeling. Curr Heart Fail Rep (2011) 0.96
New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Clin Exp Nephrol (2012) 0.95
Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes. Diabetes Care (2013) 0.94
Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1. Cardiovasc Diabetol (2014) 0.94
Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment. Am J Physiol Endocrinol Metab (2012) 0.94
Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS One (2012) 0.93
Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol (2012) 0.93
Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS One (2014) 0.92
Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin's metabolic action in the presence of insulin resistance. Diabetes (2014) 0.92
Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud (2013) 0.91
Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol (2014) 0.91
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides (2009) 0.90
The vascular endothelium in diabetes--a therapeutic target? Rev Endocr Metab Disord (2013) 0.89
Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes (2013) 0.89
Cardiovascular effects of incretin-based therapies. Rev Diabet Stud (2011) 0.88
Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol (2014) 0.88
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Ther (2015) 0.88
The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure. Cardiovasc Ultrasound (2011) 0.88
Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res (2012) 0.86
Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production. Cardiovasc Diabetol (2014) 0.86
Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis. Med Sci Monit (2012) 0.86
Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc Diabetol (2015) 0.85
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists. Rev Diabet Stud (2009) 0.85
GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism (2013) 0.85
Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J Transl Med (2013) 0.84
Effects of nitric oxide synthase inhibition with or without cyclooxygenase-2 inhibition on resting haemodynamics and responses to exendin-4. Br J Pharmacol (2006) 0.84
Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med (2008) 0.84
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag (2006) 0.83
Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model. PLoS One (2014) 0.83
The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial. PLoS Med (2016) 0.83
Efficacy of increased resistant starch consumption in human type 2 diabetes. Endocr Connect (2014) 0.83
The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol (2013) 0.83
GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci (Lond) (2014) 0.83
Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow. Exp Biol Med (Maywood) (2012) 0.83
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag (2009) 0.83
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2013) 0.83
Treating coronary disease and the impact of endothelial dysfunction. Prog Cardiovasc Dis (2014) 0.83
The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report. Cardiovasc Diabetol (2014) 0.82
Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm. J Am Heart Assoc (2014) 0.82
Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocr Connect (2014) 0.82
Incretin-Based Therapy for Prevention of Diabetic Vascular Complications. J Diabetes Res (2015) 0.82
Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways. Cardiovasc Diabetol (2015) 0.81
The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice. Exp Diabetes Res (2012) 0.81
Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes. Cardiovasc Diabetol (2013) 0.81
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol (2014) 0.80
Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists? Clin Res Cardiol (2008) 0.80
Direct cardiovascular effects of glucagon like peptide-1. Diabetol Metab Syndr (2013) 0.80
Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Ther Clin Risk Manag (2010) 0.80
Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian J Endocrinol Metab (2011) 0.80
Do incretins improve endothelial function? Cardiovasc Diabetol (2014) 0.80
Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2015) 0.80
Pleiotropic effects of incretins. Indian J Endocrinol Metab (2012) 0.80
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag (2016) 0.79
A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature (2012) 11.68
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med (2003) 4.69
Interleukin-6-deficient mice develop mature-onset obesity. Nat Med (2002) 4.47
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet (2002) 4.29
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes (2004) 4.09
Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med (2002) 3.55
Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat Genet (2011) 3.46
BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell (2005) 3.44
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
Hemifusion in SNARE-mediated membrane fusion. Nat Struct Mol Biol (2005) 3.33
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
The Drosophila HP1 homolog Rhino is required for transposon silencing and piRNA production by dual-strand clusters. Cell (2009) 3.13
Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis (2007) 3.01
Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. Diabetologia (2014) 3.01
Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. Nature (2007) 3.01
Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature (2012) 2.83
Gcn5 promotes acetylation, eviction, and methylation of nucleosomes in transcribed coding regions. Mol Cell (2007) 2.71
Multiple intermediates in SNARE-induced membrane fusion. Proc Natl Acad Sci U S A (2006) 2.65
Structural variation in two human genomes mapped at single-nucleotide resolution by whole genome de novo assembly. Nat Biotechnol (2011) 2.45
The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci U S A (2004) 2.41
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34
Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol (2010) 2.33
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J (2011) 2.32
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr (2005) 2.25
MicroRNA-206 colocalizes with ribosome-rich regions in both the nucleolus and cytoplasm of rat myogenic cells. Proc Natl Acad Sci U S A (2006) 2.15
The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome. Nat Biotechnol (2012) 2.14
Domains of eIF1A that mediate binding to eIF2, eIF3 and eIF5B and promote ternary complex recruitment in vivo. EMBO J (2003) 2.12
Interactions of eukaryotic translation initiation factor 3 (eIF3) subunit NIP1/c with eIF1 and eIF5 promote preinitiation complex assembly and regulate start codon selection. Mol Cell Biol (2004) 2.09
Chaperone-mediated pathway of proteasome regulatory particle assembly. Nature (2009) 2.07
Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene (2002) 2.03
Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial. Diabetologia (2014) 2.02
NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Nature (2008) 2.01
Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg (2005) 1.99
The bHLH genes GLABRA3 (GL3) and ENHANCER OF GLABRA3 (EGL3) specify epidermal cell fate in the Arabidopsis root. Development (2003) 1.86
Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res (2002) 1.81
Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. Endocrinology (2006) 1.80
Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood (2003) 1.78
Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. Blood (2005) 1.73
GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept (2003) 1.70
Generation of a functional and durable vascular niche by the adenoviral E4ORF1 gene. Proc Natl Acad Sci U S A (2008) 1.69
Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest (2005) 1.68
VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest (2008) 1.68
Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol (2004) 1.68
Laboratory surge response to pandemic (H1N1) 2009 outbreak, New York City metropolitan area, USA. Emerg Infect Dis (2010) 1.67
P-TEFb is not an essential elongation factor for the intronless human U2 snRNA and histone H2b genes. EMBO J (2005) 1.66
Continuous locomotion-mode identification for prosthetic legs based on neuromuscular-mechanical fusion. IEEE Trans Biomed Eng (2011) 1.65
Structure of a RSC-nucleosome complex and insights into chromatin remodeling. Nat Struct Mol Biol (2008) 1.62
G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. Pharmacol Ther (2007) 1.60
Protein kinase C delta mediates arterial injury responses through regulation of vascular smooth muscle cell apoptosis. Cardiovasc Res (2009) 1.59
Intrarenal transfer of an intracellular fluorescent fusion of angiotensin II selectively in proximal tubules increases blood pressure in rats and mice. Am J Physiol Renal Physiol (2011) 1.59
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept (2005) 1.56
Membrane fusion induced by neuronal SNAREs transits through hemifusion. J Biol Chem (2005) 1.56
Effects of everyday life events on glucose, insulin, and glucagon dynamics in continuous subcutaneous insulin infusion-treated type 1 diabetes: collection of clinical data for glucose modeling. Diabetes Technol Ther (2011) 1.55
The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. Nat Med (2007) 1.55
Mature-onset obesity in interleukin-1 receptor I knockout mice. Diabetes (2006) 1.55
Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology (2003) 1.53
Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis (2013) 1.53
Bis[5-(2-pyrid-yl)pyrazine-2-carbonitrile]-silver(I) tetra-fluorido-borate. Acta Crystallogr Sect E Struct Rep Online (2010) 1.51
Determination of acetolactate synthase activity and protein content of oilseed rape (Brassica napus L.) leaves using visible/near-infrared spectroscopy. Anal Chim Acta (2008) 1.51
Akt/Protein kinase B is required for lymphatic network formation, remodeling, and valve development. Am J Pathol (2010) 1.51
Distribution and characterization of over 1000 T-DNA tags in rice genome. Plant J (2003) 1.50
Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras. Mol Cell Biol (2010) 1.50
Somatostatin receptors. Biochim Biophys Acta (2003) 1.49
Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab (2006) 1.49
Interdependent recruitment of SAGA and Srb mediator by transcriptional activator Gcn4p. Mol Cell Biol (2005) 1.47
Both flow-mediated vasodilation procedures and acute exercise improve endothelial function in obese young men. Eur J Appl Physiol (2010) 1.47
SubpathwayMiner: a software package for flexible identification of pathways. Nucleic Acids Res (2009) 1.45
Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ Res (2003) 1.44
High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial. Diabetologia (2015) 1.44
Improved seedless hydrothermal synthesis of dense and ultralong ZnO nanowires. Nanotechnology (2011) 1.43
Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma. Tumour Biol (2015) 1.42
Mitochondrial DNA evidence for a diversified origin of workers building First Emperor of China. PLoS One (2008) 1.40
Design and fabrication of an artificial cornea based on a photolithographically patterned hydrogel construct. Biomed Microdevices (2007) 1.38
Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res (2010) 1.38
miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun (2009) 1.38
Porous 3D graphene-based bulk materials with exceptional high surface area and excellent conductivity for supercapacitors. Sci Rep (2013) 1.36
Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest (2006) 1.35
Invasive mechanism and management strategy of Bemisia tabaci (Gennadius) biotype B: progress report of 973 Program on invasive alien species in China. Sci China C Life Sci (2009) 1.35
Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. Cardiovasc Diabetol (2009) 1.34
Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation. J Exp Med (2010) 1.33
The tight junction protein, occludin, regulates the directional migration of epithelial cells. Dev Cell (2010) 1.32
Epithelial-mesenchymal transition (EMT) induced by TNF-α requires AKT/GSK-3β-mediated stabilization of snail in colorectal cancer. PLoS One (2013) 1.31
The C-terminal region of eukaryotic translation initiation factor 3a (eIF3a) promotes mRNA recruitment, scanning, and, together with eIF3j and the eIF3b RNA recognition motif, selection of AUG start codons. Mol Cell Biol (2010) 1.31
Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls. Breast Cancer Res Treat (2010) 1.31
Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol (2009) 1.31
An essential role for the RNA-binding protein Smaug during the Drosophila maternal-to-zygotic transition. Development (2009) 1.31
Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab (2004) 1.28
Real-time video imaging of protease expression in vivo. Theranostics (2011) 1.27
Bright and color-saturated emission from blue light-emitting diodes based on solution-processed colloidal nanocrystal quantum dots. Nano Lett (2007) 1.27
Improved beta-cell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab (2003) 1.26
Rice breeding in the post-genomics era: from concept to practice. Curr Opin Plant Biol (2013) 1.25
Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett (2011) 1.24
A role for monoubiquitinated FANCD2 at telomeres in ALT cells. Nucleic Acids Res (2009) 1.24
Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer (2012) 1.23
A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition. Mol Cell Biol (2011) 1.23